Kexiang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kexiang Liu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Huiying Wu
Department of Ultrasonic Diagnosis, The Second Hospital of Jilin University, Changchun
2 shared publicationsQianchuang Sun
Department of Anesthesiology
2 shared publicationsShuyan Liu
Department of Anesthesiology
2 shared publications- Zhenxiang Pan
Department of Anesthesiology
2 shared publications He Ma
Department of Anesthesiology
1 shared publicationMeidan Fang
Department of Anesthesiology
1 shared publication
Latest Publications
- Open Access
- 1 April 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (14) , e19614
Clinical analgesic efficacy of pectoral nerve block in patients undergoing breast cancer surgery
Background: Breast cancer is the most commonly diagnosed cancer in women, and more than half of breast surgery patients experience severe acute postoperative pain. This meta-analysis is designed to examine the clinical analgesic efficacy of Pecs block in patients undergoing breast cancer surgery. Methods: An electronic literature search of the Library of PubMed, EMBASE, Cochrane Library, and Web of Science databases was conducted to collect randomized controlled trials (RCTs) from inception to November 2018. These RCTs compared the effect of Pecs block in combination with general anesthesia (GA) to GA alone in mastectomy surgery. Pain scores, intraoperative and postoperative opioid consumption, time to first request for analgesia, and incidence of postoperative nausea and vomiting were analyzed. Results: Thirteen RCTs with 940 patients were included in our analysis. The use of Pecs block significantly reduced pain scores in the postanesthesia care unit (weighted mean difference [WMD] = −1.90; 95% confidence interval [CI], −2.90 to −0.91; P < .001) and at 24 hours after surgery (WMD = −1.01; 95% CI, −1.64 to −0.38; P < .001). Moreover, Pecs block decreased postoperative opioid consumption in the postanesthesia care unit (WMD = −1.93; 95% CI, −3.51 to −0.34; P = .017) and at 24 hours (WMD = −11.88; 95% CI, −15.50 to −8.26; P < .001). Pecs block also reduced intraoperative opioid consumption (WMD = −85.52; 95% CI, −121.47 to −49.56; P < .001) and prolonged the time to first analgesic request (WMD = 296.69; 95% CI, 139.91–453.48; P < .001). There were no statistically significant differences in postoperative nausea and vomiting and block-related complications. Conclusions: Adding Pecs block to GA procedure results in lower pain scores, less opioid consumption and longer time to first analgesic request in patients undergoing breast cancer surgery compared to GA procedure alone.
- 1 April 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (14) , e19614
Open AccessClinical analgesic efficacy of pectoral nerve block in patients undergoing breast cancer surgery
Background: Breast cancer is the most commonly diagnosed cancer in women, and more than half of breast surgery patients experience severe acute postoperative pain. This meta-analysis is designed to examine the clinical analgesic efficacy of Pecs block in patients undergoing breast cancer surgery. Methods: An electronic literature search of the Library of PubMed, EMBASE, Cochrane Library, and Web of Science databases was conducted to collect randomized controlled trials (RCTs) from inception to November 2018. These RCTs compared the effect of Pecs block in combination with general anesthesia (GA) to GA alone in mastectomy surgery. Pain scores, intraoperative and postoperative opioid consumption, time to first request for analgesia, and incidence of postoperative nausea and vomiting were analyzed. Results: Thirteen RCTs with 940 patients were included in our analysis. The use of Pecs block significantly reduced pain scores in the postanesthesia care unit (weighted mean difference [WMD] = −1.90; 95% confidence interval [CI], −2.90 to −0.91; P < .001) and at 24 hours after surgery (WMD = −1.01; 95% CI, −1.64 to −0.38; P < .001). Moreover, Pecs block decreased postoperative opioid consumption in the postanesthesia care unit (WMD = −1.93; 95% CI, −3.51 to −0.34; P = .017) and at 24 hours (WMD = −11.88; 95% CI, −15.50 to −8.26; P < .001). Pecs block also reduced intraoperative opioid consumption (WMD = −85.52; 95% CI, −121.47 to −49.56; P < .001) and prolonged the time to first analgesic request (WMD = 296.69; 95% CI, 139.91–453.48; P < .001). There were no statistically significant differences in postoperative nausea and vomiting and block-related complications. Conclusions: Adding Pecs block to GA procedure results in lower pain scores, less opioid consumption and longer time to first analgesic request in patients undergoing breast cancer surgery compared to GA procedure alone.
- Open Access
- 1 April 2019
- Published by Wolters Kluwer Health in The Clinical Journal of Pain
- Vol. 35 (4) , 375-384
Dexmedetomidine as an Adjuvant to Local Anesthetics in Transversus Abdominis Plane Block
Objectives: The objective of this meta-analysis was to evaluate the analgesic effects of dexmedetomidine (DEX) in transversus abdominis plane (TAP) blocks for abdominal surgery.Methods: Electronic databases, including PubMed, EMBASE, Chinese National Knowledge Infrastructure (CNKI), Wan Fang, and the Cochrane Library, were conducted to collect the randomized controlled trials (RCTs) from inception to March 2018. RCTs investigating the impact of adding DEX to local anesthetics for TAP blocks were included in this analysis. Pain scores (at rest and movement), opioid consumption, the duration of the TAP block and the common adverse effects were analyzed.Results: Twenty published trials including 1212 patients met the inclusion criteria. The addition of DEX significantly reduced pain scores 8 hours postoperatively at rest (WMD, −0.78; 95% CI, −1.27 to −0.30;P=0.001), 4 hours postoperatively on movement (WMD, −1.13; 95% CI, −1.65 to −0.60;PPP<0.001). It did not affect the incidence of postoperative nausea and vomiting, hypotension, bradycardia, somnolence, or pruritus.Conclusions: DEX is a potential anesthetic adjuvant that can facilitate better postoperative analgesia, reduce postoperative analgesic requirements, and prolong the local anesthetic effect when administered in TAP blocks.
- 1 April 2019
- Published by Wolters Kluwer Health in The Clinical Journal of Pain
- Vol. 35 (4) , 375-384
Open AccessDexmedetomidine as an Adjuvant to Local Anesthetics in Transversus Abdominis Plane Block
Objectives: The objective of this meta-analysis was to evaluate the analgesic effects of dexmedetomidine (DEX) in transversus abdominis plane (TAP) blocks for abdominal surgery.Methods: Electronic databases, including PubMed, EMBASE, Chinese National Knowledge Infrastructure (CNKI), Wan Fang, and the Cochrane Library, were conducted to collect the randomized controlled trials (RCTs) from inception to March 2018. RCTs investigating the impact of adding DEX to local anesthetics for TAP blocks were included in this analysis. Pain scores (at rest and movement), opioid consumption, the duration of the TAP block and the common adverse effects were analyzed.Results: Twenty published trials including 1212 patients met the inclusion criteria. The addition of DEX significantly reduced pain scores 8 hours postoperatively at rest (WMD, −0.78; 95% CI, −1.27 to −0.30;P=0.001), 4 hours postoperatively on movement (WMD, −1.13; 95% CI, −1.65 to −0.60;PPP<0.001). It did not affect the incidence of postoperative nausea and vomiting, hypotension, bradycardia, somnolence, or pruritus.Conclusions: DEX is a potential anesthetic adjuvant that can facilitate better postoperative analgesia, reduce postoperative analgesic requirements, and prolong the local anesthetic effect when administered in TAP blocks.